Search for: "RONALD DANIELS" Results 661 - 667 of 667
Sorted by Relevance | Sort by Date
RSS Subscribe: 20 results | 100 results
2 Oct 2008, 7:43 pm
” Strine concludes with the 1985 case arising from Ronald Perelman’s hostile bid for Revlon Inc., whose French CEO, Michel Bergerac, Strine says, had “a strong personal antipathy” for his antagonist, “some Jewish guy from Philadelphia. [read post]
28 Jan 2021, 8:30 pm by Jim Sedor
National/Federal Beau Biden Foundation to Deny Lobbyist Donations, Make Major Donors Public The Hill – Alex Gangitano | Published: 1/21/2021 The Beau Biden Foundation for the Protection of Children, which works to combat child abuse and was named after President Biden’s late son, told donors it will make changes to increase transparency. [read post]
9 Dec 2010, 9:03 pm by Adam Thierer
Wow, what a year for cyberlaw and information technology policy books! [read post]
17 Jun 2019, 2:17 pm by Erik J. Heels
17 Seconds #61 – A Publication For Clients And Other VIPs Of Clocktower. [read post]
31 Aug 2015, 10:50 am
I’ve recently been blogging about my new article, The Inherent-Powers Corollary: Judicial Non-Delegation and Federal Common Law, which I’ve posted to SSRN. [read post]
17 Mar 2021, 5:55 am by Kevin Kaufman
Table of Contents Key Findings Introduction R&D Tax Incentives for Innovation R&D Tax Subsidies for Innovation in OECD Countries — Tax Preferences for R&D Expenses — Measuring Tax Subsidies for R&D Spending — Patent Boxes in OECD Countries The Impacts of Tax Preferences on Innovation — Cross-border Shifting and Beggar-Thy-Neighbor Effects A Neutral Tax Policy Approach to Business Investment Conclusion Appendix Key Findings Tax preferences for research and… [read post]
13 Apr 2024, 3:33 pm by admin
Prelude to Litigation Phenylpropanolamine (PPA) was a widely used direct α-adrenergic agonist used as a medication to control cold symptoms and to suppress appetite for weight loss.[1] In 1972, an over-the-counter (OTC) Advisory Review Panel considered the safety and efficacy of PPA-containing nasal decongestant medications, leading, in 1976, to a recommendation that the agency label these medications as “generally recognized as safe and effective. [read post]